Sunshine Lake Pharma Co., Ltd. (06887.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 36.96

From 52W high−32.40%

Volume231100.00

Market capHKD 11.69B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

HKD 36.96

From 52W high

−32.40%

Volume

231100.00

Market cap

HKD 11.69B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

44.9

MomentumView details →

1D Return

−1.52%

YTD Return

−20.18%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

−1.52%

YTD Return

−20.18%

1Y Return

−27.20%

RSI (14)

44.9

vs 50D SMA

−0.89%

vs 200D SMA

−9.73%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Sunshine Lake Pharma's first domestic insulin glargine received FDA approval and achieved commercial shipment in the United States, securing overseas orders exceeding 18 million units.20d ago

Sunshine Lake Pharma issued a profit warning, expecting a net loss of about 590 million RMB for the first half of 2026, an increase of about 540 million RMB compared to the same period last year.26d ago

Similar companies

Ab&B Bio Tech Co Ltd.02627.HK 微芯生物688321.SH 国邦医药605507.SH XD国药现600420.SH 浙江医药600216.SH Consun Pharmaceutical Group Limited01681.HK Find similar companies →

Latest newsMore news →

Sunshine Lake Pharma's first domestic insulin glargine received FDA approval and achieved commercial shipment in the United States, securing overseas orders exceeding 18 million units.20d ago Sunshine Lake Pharma issued a profit warning, expecting a net loss of about 590 million RMB for the first half of 2026, an increase of about 540 million RMB compared to the same period last year.26d ago Sunshine Lake Pharma's self-developed insulin glargine injection received FDA approval for marketing in the United States.62d ago